DoW Ovarian Cancer, Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA
Program funding
$5,600,000
- Opportunity #
- HT942526OCRPCTA
- Agency
- Defense Health Agency Contracting Activity - DHACA
- ALN (CFDA)
- 12.420
- Status
- posted
- Posted
- May 4, 2026
- Closes
- Oct 1, 2026
- Funding instrument
- Grant
- Category
- Science and Technology and other Research and Development
- Cost sharing required
- No
Who can apply
- •Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Synopsis
Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.
Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Contact
Christopher Meinberg Grantor · help@ebrap.org